Skip to main navigation
Skip to search
Skip to main content
University of Portsmouth Home
Help & FAQ
Link opens in a new tab
Search content at University of Portsmouth
Home
Profiles
Organisations
Research outputs
Student theses
Datasets
Projects
Activities
Prizes
Press/Media
Equipment
Inhaled heparin in cystic fibrosis
D. Serisier
, Jan Shute
, P. Hockey
, Bernard Higgins
, J. Conway
, M. Carroll
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Inhaled heparin in cystic fibrosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
INIS
fibrosis
100%
heparin
100%
inflammation
50%
adults
37%
volume
25%
safety
25%
clearance
25%
doses
25%
inhalation
25%
data
12%
evaluation
12%
in vivo
12%
risks
12%
symptoms
12%
secretion
12%
blood coagulation
12%
washout
12%
Medicine and Dentistry
Cystic Fibrosis
100%
Heparin
100%
Sputum
37%
Forced Expiratory Volume
25%
Anti-Inflammatory Drug
25%
Mucolytic Agent
25%
Infection
12%
Adverse Event
12%
Bleeding
12%
Drug Megadose
12%
Blood Clotting
12%
Placebo
12%
Secretion (Process)
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cystic Fibrosis
100%
Heparin
100%
Anti-Inflammatory Drug
25%
Mucolytic Agent
25%
Tolerability
12%
Infection
12%
Placebo
12%
Inflammation
12%
Adverse Event
12%
Bleeding
12%
Nursing and Health Professions
Cystic Fibrosis
100%
Heparin
100%
Forced Expiratory Volume
25%
Pilot Study
12%
Inflammation
12%
Placebo
12%
Infection
12%
Bleeding
12%
Drug Megadose
12%
Adverse Event
12%